Skip to content

Use of Ayurvedic Formulation as hair promoting factor especially on head and face.

A comparative clinical study to assess Keshya efficacy of Yashtimadhuk Taila Nasya and Basti by evaluating Androgen Levels.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/06/034147
Enrollment
40
Registered
2021-06-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L64- Androgenic alopecia

Interventions

Intervention1: Group B: 1. Administration of Utkleshan Basti with Tila Taila in increasing dose (20 ml per day) starting from 40ml for 5 days. 2. Followed by Shodhan Basti by Yashtimadhuk Kwath for 3

Sponsors

National Institute of Ayurveda Jaipur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients having Hair fall, low density of beard. 2.Patients between 20-45 years age group. 3.Only male patients. 4.Patient willing for the treatment & willing to sign written consent form. 5.Patients fit for Nasya and Basti Karma.

Exclusion criteria

Exclusion criteria: 1.Patient who have hair fall due to other conditions like genetic disorder, radiotherapy, chemotherapy after pregnancy, dandruff, bacterial infection etc. 2.Alopecia totalis and Alopecia universalis patients will be excluded. 3.Patients suffering from systemic disorders as Cardiac Problem, Uncontrolled Diabetes mellitus, Uncontrolled Hypertension, Paralysis, Malignancy, HIV, HBsAg, Leprosy. 4.Patients unfit for Nasya and Basti karma.

Design outcomes

Primary

MeasureTime frame
Hair Combing TestTimepoint: 8 weeks

Secondary

MeasureTime frame
Density of hairsTimepoint: 8 weeks

Countries

India

Contacts

Public ContactProf Dr Surendra Vedpathak

National Institute of Ayurveda

drsurendravedpathak50@gmail.com7030309088

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026